DWP708 / Daewoong Pharma - LARVOL DELTA

A multi-center, randomized, double-blind, placebo-controlled, therapeutic exploratory, phase II clinical trial for the efficacy investigation and safety evaluation of DWP708 for treating epidermal growth factor receptor inhibitor related skin toxicities (ESMO 2025) - P2 | "Conclusions DWP708 demonstrated a gradual improvement over time compared to placebo with a favorable safety profile. Clinically meaningful improvements in subjective satisfaction suggest DWP708 may be an effective and safe treatment for ERSE, supporting the need for further confirmatory studies."

Clinical • P2 data • Oncology • EGFR

DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities (clinicaltrials.gov) - P2 | N=96 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Completed | Trial completion date: Feb 2023 ➔ Dec 2023 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Trial completion • Trial completion date • Trial primary completion date

Efficacy Investigation and Safety Evaluation of DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New P2 trial • EGFR